文献速递淋巴瘤

经典型霍奇金淋巴瘤循环游离DNA拷贝数变异图谱:KU Leuven与LYSA联合研究

The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA.
PubMed 文献 · Blood Adv · 2021-01-01

该研究前瞻性采集177例初诊、多为早期经典型霍奇金淋巴瘤(cHL)患者的循环游离DNA(cfDNA),以低覆盖度(0.26×)测序并用ichorCNA分析拷贝数变异(CNA)与克隆分数。超过90%患者cfDNA中可检出CNA,明确了高频获得与缺失区域并发现新的复发性CNA;ctDNA浓度与晚期疾病、男性、广泛淋巴结病变、血沉升高、代谢肿瘤体积及HRS细胞负荷相关,治疗开始后CNA与ctDNA迅速下降,CNA持续存在与复发概率增加相关。

要点

  • 超过90%的初诊cHL患者cfDNA中可检出拷贝数变异,支持ctDNA作为HRS基因组分析入口。
  • 高频获得包括2p16(69%)、5p14(50%)、12q13(50%)、9p24(50%);高频缺失包括13q(57%)、6q25-q27(55%)。
  • 治疗开始后CNA与ctDNA迅速下降,CNA持续存在与复发概率增加相关。

核心结论

  • cfDNA低覆盖度测序可描绘cHL的CNA图谱,超过90%患者存在CNA,并支持ctDNA用于早期疗效评估。

研究设计与样本

  • 前瞻性纳入177例初诊、多为早期cHL患者,来自比利时Leuven单中心研究(n=59)和LYSA多中心BREACH研究(n=118)。
  • 对cfDNA进行低覆盖度(0.26×)测序,并用ichorCNA分析基于读深的拷贝数谱和cfDNA中估计克隆分数。

主要发现

  • 初诊时cHL患者的cfDNA浓度、估计克隆分数和ctDNA浓度显著高于对照。
  • 超过90%患者在cfDNA中检出CNA;高频获得为2p16(69%)、5p14(50%)、12q13(50%)、9p24(50%)、5q(44%)、17q(43%)、2q(41%)。
  • 高频缺失为13q(57%)、6q25-q27(55%)、4q35(50%)、11q23(44%)、8p21(43%)。
  • 新发现的复发性CNA包括3p13-p26缺失、12q21-q24缺失和15q21-q26获得。
  • 初诊时ctDNA浓度与晚期疾病、男性、广泛淋巴结病变、血沉升高、代谢肿瘤体积和HRS细胞负荷相关。

临床怎么用

  • 可考虑以cfDNA低覆盖度测序获取cHL的CNA谱,作为HRS基因组分析的微创途径。
  • 治疗开始后动态监测ctDNA/CNA下降情况,CNA持续存在提示复发风险增加,可用于早期疗效评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The low abundance of Hodgkin/Reed-Sternberg (HRS) cells in lymph node biopsies in classical Hodgkin lymphoma (cHL) complicates the analysis of somatic genetic alterations in HRS cells. As circulating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA) from HRS cells, we prospectively collected cfDNA from 177 patients with newly diagnosed, mostly early-stage cHL in a monocentric study at Leuven, Belgium (n = 59) and the multicentric BREACH study by Lymphoma Study Association (n = 118). To catalog the patterns and frequencies of genomic copy number aberrations (CNAs), cfDNA was sequenced at low coverage (0.26×), and data were analyzed with ichorCNA to yield read depth-based copy number profiles and estimated clonal fractions in cfDNA. At diagnosis, the cfDNA concentration, estimated clonal fraction, and ctDNA concentration were significantly higher in cHL cases than controls. More than 90% of patients exhibited CNAs in cfDNA. The most frequent gains encompassed 2p16 (69%), 5p14 (50%), 12q13 (50%), 9p24 (50%), 5q (44%), 17q (43%), 2q (41%). Losses mostly affected 13q (57%), 6q25-q27 (55%), 4q35 (50%), 11q23 (44%), 8p21 (43%). In addition, we identified loss of 3p13-p26 and of 12q21-q24 and gain of 15q21-q26 as novel recurrent CNAs in cHL. At diagnosis, ctDNA concentration was associated with advanced disease, male sex, extensive nodal disease, elevated erythrocyte sedimentation rate, metabolic tumor volume, and HRS cell burden. CNAs and ctDNA rapidly diminished upon treatment initiation, and persistence of CNAs was associated with increased probability of relapse. This study endorses the development of ctDNA as gateway to the HRS genome and substrate for early disease response evaluation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Buedts L, Wlodarska I, Finalet-Ferreiro J, et al. The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Adv. 2021. PMID: 33843986. doi:10.1182/bloodadvances.2020003039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。